Letter

Approval of inhaled insulin in Europe and United States

BMJ 2006; 332 doi: 10.1136/bmj.332.7543.730-b (Published 23 March 2006)
Cite this as: BMJ 2006;332:730.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Bruce Charlesworth, head of RMRS and medical affairs (bruce.charlesworth@pfizer.com)
  1. Pfizer Limited, Walton Oaks, Walton-on-the-Hill, Tadworth, Surrey KT20 7NS

    EDITOR—We wish to respond to several points in the news item by Lenzer on the approval of inhaled insulin.1

    Firstly, the article states that critics say that Exubera fails to control postprandial glucose presentations as well as subcutaneous insulin. In fact, in clinical trials Exubera is comparable or superior to subcutaneous human insulin in terms of postprandial glucose control.2–4

    Secondly, the article raises concerns about the pulmonary effects of Exubera. Pfizer has …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular